Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

588P - Androgen changes after enzalutamide or abiraterone plus prednisone in men with castration-resistant prostate cancer (HEAT): Results from a randomised clinical trial

Date

16 Sep 2021

Session

ePoster Display

Topics

Cytotoxic Therapy;  Clinical Research

Tumour Site

Prostate Cancer

Presenters

Klara Kvorning Ternov

Citation

Annals of Oncology (2021) 32 (suppl_5): S626-S677. 10.1016/annonc/annonc702

Authors

K. Kvorning Ternov, J. Sønksen, M. Fode, H. Lindberg, C. Kistorp, R. Bisbjerg, J. Faber, G. Palapattu, P. Østergren

Author affiliations

  • Urology, Herlev and Gentofte Hospital, 2730 - Herlev/DK

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 588P

Background

Enzalutamide (ENZ) and abiraterone acetate plus prednisone (AAP) are both androgen receptor targeting treatments for metastatic castration-resistant prostate cancer (mCRPC). AAP inhibits the androgen production, whereas ENZ blocks the androgen receptor signalling. Herein, we evaluate and compare treatment changes in serum androgens for ENZ and AAP.

Methods

First-line ENZ (160 mg/day) and AAP (1000 mg abiraterone acetate and 10 mg prednisone/day) for mCRPC were compared in this investigator-initiated open-labelled randomised (1:1) phase IV trial. Eligible patients had progressive metastatic prostate cancer on androgen deprivation therapy (testosterone <1.7nmol/L). Fasting serum androgens, including testosterone and precursors to testosterone (androstenedione, dehydroepiandrosterone sulphate [DHEAS] and 17-Hydroxyprogesterone [17-OHP]), were measured by the gold standard assay liquid chromatography – tandem mass spectrometry before 11 am at baseline and at 12-week post-intervention. The treatment difference in changed androgens was compared with mixed models analysis, and the within-subject change for each treatment group was analysed with paired samples t-test. This was a pre-planned secondary endpoint (EudraCT 2017-000099-27).

Results

From June 2017 to September 2019, 170 participants were randomized to receive ENZ (n=84 analysed) or AAP (n=85 analysed). A larger decline in testosterone, androstenedione and DHEAS was found for AAP than ENZ. In the ENZ group, testosterone and DHEAS increased from baseline to week 12, whereas decreased in the AAP group. No treatment difference was found for 17-OHP (Table). Table: 588P

Enzalutamide Abiraterone Treatment difference Mean (95 CI%)
Baseline Mean (SD) 12 week-change Mean (95 CI%) Baseline Mean (SD) 12-week change Mean (95 CI%)
Testosterone (nmol/L) 0.37 (0.23) 0.15 (0.10; 0.20) P<0.0001 0.34 (0.21) -0.23 (-0.28; -0.19) P<0.0001 -0.40 (-0.46; -0.34) P<0.0001
Androstenedione (nmol/L) 1.74 (0.92) 0.10 (-0.07; 0.26) P=0.2 1.53 (0.84) -1.24 (-1.41; -1.06) P<0.0001 -1.44 (-1.63; -1.25) P<0.0001
Dehydroepiandrosterone sulphate (μmol/L) 1.66 (1.37) 0.12 (0.02; 0.23) P=0.02 1.69 (1.42) -1.60 (-1.89; -1.32) P<0.0001 -1.71 (-1.91; -1.51) P<0.0001
17-Hydroxyprogesterone (nmol/L) 0.78 (0.58) 0.062 (-0.07; 0.20) 0.61 (0.43) 0.042 (-0.10; 0.18) -0.12 (-0.30; 0.05)

Conclusions

In men on androgen deprivation therapy, with remaining androgens mainly derived from the adrenal production, ENZ and AAP both inhibit the androgen stimulation of prostate cancer, but by different mechanism of action resulting in different androgen profiles.

Clinical trial identification

EudraCT 2017-000099-27.

Editorial acknowledgement

Legal entity responsible for the study

J. Sønksen.

Funding

This trial was mainly supported by funding from Herlev and Gentofte University Hospital. Additional grants were received from the following independent foundations: Scandinavian Prostate Cancer Group research fund, Herlev and Gentofte internal research fund, ‘Torben og Alice Frimodts’ foundation, and ‘Christina Larsen og Dommer Ellen Larsen’ Scholarship.

Disclosure

M. Fode: Other, Advisory Board: Ferring; Other, Advisory Board: Astellas. H. Lindberg: Other, Advisory Role: MSD; Financial Interests, Advisory Role: Janssen; Financial Interests, Advisory Role: Sanofi-Aventis. P. Østergren: Financial Interests, Invited Speaker: Astellas; Financial Interests, Invited Speaker: Ipsen; Financial Interests, Invited Speaker: Ferring. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.